...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer gene therapy >Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity
【24h】

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity

机译：由人类端粒酶启动子驱动的条件复制腺病毒可提供广谱抗肿瘤活性，而无肝毒性

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The human telomerase reverse transcriptase (hTERT) promoter is known to selectively drive transgene expression in many human cancer cells expressing hTERT, the catalytic component of the telomerase ribonucleoprotein complex. We have created a conditionally replicative adenovirus where the viral E1A gene, which is required for viral replication, is under the control of the hTERT promoter (AdhTERTp-E1A). In vitro studies with AdhTERTp-E1A virus on a variety of normal and tumor cell lines have shown that viral genome replication and productive infection is primarily restricted to telomerase-positive tumor cells. Lytic replication was not observed in normal primary fibroblast and epithelial cell lines tested. In vivo administration of the virus into nude mice bearing human liver or prostate tumor xenografts produced significant tumor reduction and, in some cases, resulted in complete tumor regression. AdhTERTp-E1A virus did not actively express E1A in normal mouse liver, in contrast to a control oncolytic vector in which the CMV promoter (AdCMVp-E1A) was driving the E1A gene. In addition, AdhTERTp-E1A virus produced no apparent toxicity to the liver in systemically injected mice. The hTERT promoter-driven oncolytic virus also produced significantly less toxicity to freshly cultured human hepatocytes. These studies demonstrate that an oncolytic virus driven by the telomerase promoter can be used to effectively kill a wide variety of cancer cell types and has the potential to treat primary and metastatic cancer of diverse origins.
机译：已知人类端粒酶逆转录酶（hTERT）启动子在表达hTERT（端粒酶核糖核蛋白复合体的催化成分）的许多人类癌细胞中选择性驱动转基因表达。我们创建了条件复制腺病毒，其中病毒复制所需的病毒E1A基因在hTERT启动子（AdhTERTp-E1A）的控制下。用AdhTERTp-E1A病毒对多种正常细胞和肿瘤细胞进行的体外研究表明，病毒基因组复制和生产性感染主要限于端粒酶阳性的肿瘤细胞。在正常的原代成纤维细胞和上皮细胞系中未观察到裂解复制。在携带人肝或前列腺肿瘤异种移植物的裸鼠体内对该病毒的体内给药可显着减少肿瘤，在某些情况下可导致肿瘤完全消退。与其中CMV启动子（AdCMVp-E1A）驱动E1A基因的对照溶瘤载体相反，AdhTERTp-E1A病毒在正常小鼠肝脏中不主动表达E1A。另外，在全身注射的小鼠中，AdhTERTp-E1A病毒对肝脏没有产生明显的毒性。 hTERT启动子驱动的溶瘤病毒对新鲜培养的人肝细胞的毒性也大大降低。这些研究表明，由端粒酶启动子驱动的溶瘤病毒可用于有效杀死多种类型的癌细胞，并具有治疗多种来源的原发性和转移性癌症的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号